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ABSTRACT
A simple, static contact mapping algorithm has been developed as a first step at identifying potential peptide biomimetics
from protein interaction partner structure files. This rapid and simple mapping algorithm, “OpenContact” provides
screened or parsed protein interaction files based on specified criteria for interatomic separation distances and interatomic
potential interactions. The algorithm, which uses all-atom Amber03 force field models, was blindly tested on several unrelated cases from the literature where potential peptide mimetics have been experimentally developed to varying degrees of
success. In all cases, the screening algorithm efficiently predicted proposed or potential peptide biomimetics, or close variations thereof, and provided complete atom-atom interaction data necessary for further detailed analysis and drug development. In addition, we used the static parsing/mapping method to develop a peptide mimetic to the cancer protein target,
epidermal growth factor receptor. In this case, secondary, loop structure for the peptide was indicated from the intraprotein mapping, and the peptide was subsequently synthesized and shown to exhibit successful binding to the target protein. The case studies, which all involved experimental peptide drug advancement, illustrate many of the challenges associated with the development of peptide biomimetics, in general
Proteins 2014; 82:2253–2262.
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INTRODUCTION
Protein–protein interactions (PPIs) that underlie cell
signal pathways are a promising avenue for the development of inhibitory compounds aimed at disrupting cellular networks. Specifically, small peptide inhibitors that
mimic protein segments associated with specific residueresidue interactions (peptidyl-biomimetics) in native, cellular processes have shown success as therapeutic
agents.1 However, there are many different facets of peptide biomimetics that must be considered before moving
forward with any potential drug candidate. These facets
include, for example, extracellular versus intracellular
proteins, agonist versus antagonist actions, solubility,
specificity, residue length, nature of binding forces and
strength, and structural stability and dynamics.2
In general, intra-protein and inter-protein interactions
are characterized by regions or segments of strong atomic
charge and/or van der Waals interactions associated with

specific residues of the parent proteins. (Also referred to
as “hot spots” or “hot segments”;1 see Fig. 1) For example, regions or segments where relatively strong van der
Waals forces dominate are typically associated with
hydrophobic protein interactions, whereas regions of
strong atomic charge and partial atomic charge interactions are associated with salt bridges, hydrogen bonding,
and polar interactions. Now, these regions or segments
can potentially function in isolation as peptide mimetics
Additional Supporting Information may be found in the online version of this
article.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made
*Correspondence to: Michael H. Peters, Department of Chemical and Life Science
Engineering, Virginia Commonwealth University, 601 West Main St, Richmond,
VA 23284. E-mail: mpeters@vcu.edu
Received 15 January 2014; Revised 7 April 2014; Accepted 15 April 2014
Published online 22 April 2014 in Wiley Online Library (wileyonlinelibrary.com).
DOI: 10.1002/prot.24592

C 2014 THE AUTHORS. PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS PUBLISHED BY WILEY PERIODICALS, INC.
V

PROTEINS

2253

A. Krall et al.

Figure 1
Overview of the contact mapping strategy for peptidyl biomimetics
from protein interaction partners. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]

that may block or inhibit the formation of their parent
protein complexes. Thus, most peptide mimetics function
as antagonistic drugs in application. Clearly, there are
questions about any such region’s or segment’s effectiveness in isolation, including the maintenance of structure,
strength of binding, solubility, and so forth, but nonetheless a simple, static mapping of the interactions could
provide a rapid starting point for more detailed studies.
Recently, London et al.3 have reviewed the identification of “hot spots” or “hot segments” of PPIs and potential peptide mimetics. In the majority of cases, specific
residues or sequences of residues from the parent proteins
could be identified. Many of the current methods of peptide identification are based on different schemes of docking calculations or Free Energy calculations.1,3 In this
study, assuming that the protein partner interaction structure information is known, we describe a very simple,
transparent, and rapid static contact mapping algorithm
for parsing out key binding areas along with their associ-

ated residues. These segments or regions can then be further explored as potential peptide mimetics via more
lengthy dynamic algorithms, such as molecular dynamics
or free energy, docking algorithms, and experimental
methods. In addition, the parsing provides the specific
type and magnitude of the atom–atom interaction forces
of the associated residues based on all-atom interaction
force field models, which has uses beyond peptidyl biomimetics including mutation analysis as illustrated in one
case below. In this study, the algorithm is specifically
tested against several reported, but unrelated, experimental peptide biomimetic development examples from the
literature. In addition, we give our own example of experimental peptide development for anti-cancer therapy that
involves the successful creation of secondary, loop peptide
structure with experimentally demonstrated binding to
the target protein. The examples given here also broadly
illustrate some of the challenges and pitfalls associated
with peptide biomimetic development in general. For
completeness, we note that this method is restricted to
the development of potential peptide biomimetics from
known protein interaction partner structure files and does
not necessarily include the identification of all “druggable
hot spots”4,5 or ligand identification through peptide
data mining methods6 or docking methods involving peptide libraries and small bioactive molecules.4,7,8

MATERIALS AND METHODS
Computational

The parsing and contact mapping program is diagrammed in Figure 2. The external *.pdb file or equivalent structure file is supplied by the user. Interaction
partners (Protein A and Protein B) are specified by the
user through identification of the Chain ID in the

Figure 2
Flowchart for the parsing and contact mapping program: OpenContact. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Contact Mapping for Potential Peptide Mimetics

particular protein data bank file(s). As illustrated below,
interactions between two chains of a single protein may be
specified or two chains of a multiple protein interaction
complex. Amber039 supplies partial atomic charges and
Lennard-Jones parameters (van der Waals and Born force
constants) for all protein atoms. In the Coulombic potential calculations given here, we use a distance dependent
solvent dielectric of sigmoidal shape (D 5 0.2 Å21) following the work of Ramstein and Lavery10 as reviewed by
Smith and Pettitt.11 In this model, the dielectric constant
ranges from unity at zero separation distance between
atoms to its bulk value at  15 Å and, therefore, approximately captures solvent effects for a wide range of contact
distances. Apolar implicit solvent forces have not been
included in the results given here. For “coarse parsing” of
the interactions, atom–atom separation distances greater
than 10.5 Å are excluded. In the “fine parsing” of the interactions, an additional restriction on the atom–atom interaction potentials are specified. For all “fine parsing” results
given below, we have selected upper limits to restrict Coulombic or Lennard Jones interactions as
U  Coul  20:3

CEM Corporation. Purification (>95%) was performed
through High Performance Liquid Chromatography
using a reverse phase column. For disulfide bond formation, the peptide sample, P28, was dissolved in 0.01M
ammonium bicarbonate buffer (pH 8) at a concentration
of 0.1 mg/mL and the solution was left to stir in open
atmosphere. The progress of the reaction was monitored
by analytical HPLC (peak shifted after disulfide bond
formation). After the reaction was complete, the peptide
solution was purified and checked for mass (loss of 2
protons) using mass spectrometry.
The binding kinetics of growth factor and peptides
were measured on a Biacore 3000 instrument (GE, New
Jersey) using HBS-EP as running buffer (10 mM HEPES,
pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.15% surfactant P20). EGFR-Fc (R&D) was immobilized to CM5
sensor chip surface using standard amine-coupling chemistry by injecting the following reagents (45 mL) at a flow
rate of 5 lL/min: 0.05M N-hydroxysuccinimide, 0.2M
N,N-(3-dimethylaminopropyl)-N-ethyl-carbodiimide
mixture, EGFR-Fc (10 lg/mL in 10 mM NaAc, pH 5.0),
and 1M ethanolamine-HCl (pH 8.5).
RESULTS

or
U  LJ  20:1
respectively, where U*5U/kT with k being Boltzmann’s
constant and T is temperature (taken as 310.15 K in all
results given here). These optimized, empirical cut-offs,
the efficiency of which are demonstrated in case studies
below, ensure that only the strongest attractive interaction
potentials, for a given type, are included in the fine parsing
output results. Because of the partial atomic charges
assigned by all atom force filed models there are typically
hundreds of attractive Coulombic interactions in the
dimensionless range of (20.2,0); similar arguments apply
to the Lennard Jones attractive term. However, we note
that the fine parsing criteria given above can also be
changed by the user via the coarse parsing data.
In addition, and following Amber03 modeling,9 any
atom–atom overlaps are defined as separation distances less
than 0.9 times the average pair molecular diameter. In those
cases, the potentials are computed at this minimally selected
distance. The final coarse and fine parsing results are provided to the user in a highly manageable and friendly format
in both *.pdb and *.txt (text files) for spread sheeting, plotting, and more detailed interaction analysis, as illustrated in
the case studies below (see Supporting Information).

Experimental—EGFR/P28 kinetic binding
measurements

The peptide mimetic, P28, was synthesized using Liberty Automated Microwave Peptide Synthesizer from

Based on our methods, we have examined four different cases of protein interaction partners that have lead to
the development of peptide mimetics.
Peptide inhibitors to gp41—an envelop
glycoprotein of HIV-1

Gp41 is part of a glycoprotein complex of HIV-1 that
binds to target cell receptors CD4 and CCR-5 or CXCR4.12 Gp41 is a three-stranded coiled-coil structure that is
exposed during the viral entry process (prefusion state).
Gp41, therefore, has been a target for the development
of inhibitory compounds that bind to it and disrupt the
viral entry process. Each subunit of gp41 consists of an
N-heptad repeat unit from its N-terminal region (NHR)
and C-heptad repeat unit from the C-terminal end
(CHR) arranged in an antiparallel fashion. During fusion
the subunits fold to form a six bundle helix with three
NHR regions in the core stabilized by interactions with
three ectodomain CHR regions. The NHR and CHR
interacting regions were synthesized and structurally
determined.13 Peptide sequences based on the CHR
region (C peptides) potentially bind to the NHR region
and vice versa.14 C-peptides have been experimentally
shown to be potent inhibitors resulting in, for example,
the successful drug Fuzeon (Roche) or Enfuvirtide
(T-20).15
In the application of OpenContact for this system, the
CHR peptide (Chain ID 5 C of 1AIK.pdb)was assigned
as Protein A and the NHR peptide (Chain ID 5 N of
1AIK.pdb) was assigned as Protein B. The coarse parsing
PROTEINS
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Figure 3
a: Coarse parsing or CoarseAB.pdb file for gp41. Due to multiple, close atom contacts, the CHR domain retains its helical structure. b: Fine parsing
or FineAB.pdb file for the gp41 system. The CHR domain sequence predicted (C628–C659) has been experimentally shown to be one of the most
potent inhibitors of gp41. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

*.pdb file (CoarseAB.pdb), for contacts less than 10.5 Å,
is shown in Figure 3(a).
As seen in Figure 3(a) and in the Supporting Information, there are many more contact atoms for the CHR
unit than for NHR unit. This result is consistent with
experimental studies that show peptide inhibitors based
on CHR domain are generally more potent than NHR
domain peptides. In addition, as shown in Figure 3(b),
the fine parsing based on the Coulombic and LJ criteria
yielded a 32 residue peptide sequence (C Residues
TRP628-GLU659) almost exactly overlying a number of
known nanomolar binding peptides (C34’s and SJ-2176)
from the CHR region:14
C34: TRP628-LEU661
SJ2176: GLU630-GLU659
Figure 4(a) (Lennard Jones Potential plot) and 4(b)
(Coulombic Potential Plot) show examples using the
FineAB.txt output file for this system, where the parsing
correctly predicted the dominance of apolar C-peptide
binding to the NHR hydrophobic pocket region (N656N573) [Fig. 4(a)], as well as several important salt bridge
and polar interactions [Fig. 4(b)] (Complete output files
and spreadsheets are given in the Supporting Information.).
As noted above, OpenContact is simply a first-step at
possible peptidyl-biomimetics, and C34 peptides have
been further experimentally studied in terms of their
binding affinities, solubilities, residue variations, viral
strain variations, and so forth.14 For example, C34 peptides exhibited solubility issues in application.14 Note
that Fuzeon or DP-178 (C Residues TRY638-PHE673)
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demonstrated improved solubility and equally strong
binding, when compared with C34 peptides.14,15 Thus,
simple contact mapping will not rectify potential solubility issues of isolated peptide segments. It is also unclear
as to the role played by the additional residues of DP178 outside of the contact map, that is, residues 662–
673, although they could be associated with maintaining
the helical structure/stability of Fuzeon or a binding segment not evident from the static map (see Discussion
below). The next example demonstrates how simple contact mapping yields a small linear peptide from a larger
protein partner file.

Peptide mimetics for EphB4-EphrinB2
interactions

The PPI between membrane EphrinB2 ligand and
membrane tyrosine kinase receptor EphB4 represents a
critical signaling pathway in embryonic and tumor
angiogenesis.16,17 Inhibiting this interaction could
potentially slow angiogenesis in growing tumors and,
thus, small molecule, peptide inhibitors based on phage
display libraries16,17 or peptide mimetics1 have been
proposed. The structure of this interaction complex has
been determined17 (pdb file: 2HLE) and is used to
investigate potential peptide mimetics as given below.
In the application of OpenContact to this system, the
input files were established as follows:
Protein A: 2HLE.pdb Chain ID 5 A (EphB4 receptor)
Protein B: 2HLE.pdb Chain ID 5 B (EphrinB2 ligand)

Contact Mapping for Potential Peptide Mimetics

Figure 4
a: Lennard Jones potential plot for atom-atom interactions predicted from FineAB.txt showing a significant number of strong van der Waals interactions for this system. The dimensionless potential values are given by the colorbar. b: Coulombic potential plot for atom–atom interactions predicted from FineAB.txt showing a limited number of partial charge interactions for this system as compared to van der Waals potential
interactions. The open source Matplotlib feature of OpenContact allows the user to zoom into specific atom-atom interactions. Herein, we show
the partial atomic charge interaction predicted between O, LEU-568 of NHR and HE1, TRP-631 of CHR. All naming conventions follow the Protein Data Bank format.

The coarse parsing, shown in Figure 5, indicates a significant number of residue–residue interactions. However,
many of these interactions are associated with secondary,
beta sheet structures of the EphB4 receptor that peptide segments may not mimic in isolation. However, smaller linear
segments associated with loops and other less structured
segments could be potential inhibitor candidates.1 In particular, the coarse parsing demonstrates that previously proposed1 residues 116-128 of the EphrinB2 G-H loop (Chain
ID B shown) make intimate contact with the hydrophobic
pocket of the EphB4 receptor. This is shown more clearly in
the fine parsing *.pdb file given in Figure 6 and in the Lennard Jones plot created from FineAB.txt file (Supporting
Information). In addition, the spreadsheet created from the
FineAB.txt file (Supporting Information) concurs with London et al.1 that these specific receptor residues (116B-128B)
confer a majority of the interaction energy via a number of
strong van der Waals interactions associated with the hydrophobic pocket. In addition, however, another potential
small linear peptide mimetic is identified from a loop of the
ligand (A chain or EphB4 protein) as LYS24A-TRP32A,
which interestingly retains its structure in the coarse parsing
(Fig. 5). Ligand (membrane) based inhibitors have not been
explored for this system to our knowledge, and further analysis, such as dynamic docking, is beyond the scope of this
article; OpenContact simply provides a rapid assessment of
potential peptide mimetics for further detailed studies. As a
final note, the fine parsing from OpenContact also correctly

listed LEU95A as a significant “player” in the interactions
(with PHE120B and PRO122B); this ligand residue is
believed responsible for its selectivity to EphB416 (Supporting Information).
This example demonstrates the initial design/discovery
strategy often used for identifying potential peptide biomimetics, that is, looking for consecutively numbered contact
residues from the parent protein chain that make strong
contact with partner protein chains. Consecutive residues
are necessary to help maintain the native structure of the
isolated peptide mimetic. Although there are a number of
residues identified in the coarse and fine parsing results, as
shown for example in Figure 6, only consecutively numbered residues greater than approximately 8 are generally
considered as potential candidates.2 Thus, a significant
number of residues are required for strength in binding
and those residues should be in sequence order from the
parent protein for structure considerations. Contact mapping only provides a starting point for such an identification and further dynamic computational/experimental
studies of any potential peptide candidate identified are, of
course, still required.
Peptide inhibitors to the proto-oncogenic
transcription factor Myc-Max

The heterodimer protein complex Myc-Max (pdb ID:
1NKP) is a transcription factor in cell proliferation and
PROTEINS
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Figure 5
Coarse parsing or CoarseAB.pdb file for EphB4-EphrinB2 system. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Figure 6
Fine parsing or FineAB.pdb file for EphB4-EphrinB2 system. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Contact Mapping for Potential Peptide Mimetics

Figure 7
Myc-Max tetramer system: pdb ID: 1NKPand fine parsing or FineAB.pdb file for the Myc-Max system. Not all residue labels appeared in the fine
parsing plot due to insufficient number of residue atoms. The complete output files are given in the Supporting Information. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]

is upregulated in many different cancer types.18 The
Myc-Max heterodimer is therefore an ideal candidate for
attempted development of inhibitory compounds based
on peptide biomimetic strategies.19,20 Herein, we again
use OpenContact by choosing:
Protein A: (Myc) 1NKP.pdb Chain ID 5 A
Protein B: (Max) 1NKP.pdb Chain ID 5 B
Figure 7 shows the 1NKP.pdb structure file from the
Protein Data Bank of a tetramer complex involving two
Myc-Max heterodimers.18 The Myc protein has a socalled (N-term) Basic Region that binds to DNA promoter, followed by the secondary structures: {Helix (1)Loop – Helix(2) – Leucine zipper} (C-term). The Max
DNA binding protein has the same secondary structural
motif (b-HLH-zip) as shown. Note that the H2 region is
contiguous with the Leucine zipper region in these structural motifs.18,19
The fine structure interaction (FineAB.pdb) for this
system is also shown in Figure 7, and FineAB.txt gives all
atom-atom interactions under fine parsing (Supporting
Information). The fine parsing from OpenContact identifies the following potential peptide biomimetics from
either the Myc or Max protein:
Myc
Region:
Max
Region:

Protein: H1 Region: ARG913A-ILE928A; H2
LYS939A-ILE950A; Zipper: LEU951A-CYS984A
Protein: H1 Region: SER214B-SER228B; H2
SER238B-TYR252B; Zipper: MET253B-CYS284B

Our H1 mimetic results almost exactly overlay previously proposed, synthesized, and studied19 mimetics cMyc H1: ASN915A-ILE928A and Max H1 mimetic:
ASP216B-VAL229B. In addition, c-Myc H1 mimetics
have been developed with amino acid substitutions (peptide mimetic mutants) to improve their helical content.19 These mutants also exhibited complimentary
binding to c-Myc and have been further studied including complexing with cell penetrating polypeptides.20–22
Note that the Max peptide synthesized from the H1
region was experimentally shown to lack helical structure
with no detectable interaction with c-Myc.19 No studies
on H2 or Zipper mimetics for this system have been
reported to our knowledge. This system nicely illustrates
that not all potential helical peptide mimetics will retain
their structure in isolation from their parent protein
chain or parent protein chain partner.

EGFR-EGF system

The epidermal growth factor receptor (EGFR) family,
also called ErbB family, consists of four kinds of receptors, EGFR (ErbB1), Neu (ErbB2), ErbB3, and ErbB4.
Each receptor consists of a cytoplasmic tyrosine kinase
domain, a single transmembrane spanning region, and
an extracellular region (sEGFR), the latter of which contains approximately 620 amino acids. The extracellular
region of each receptor has four domains, L1 and L2 (or
PROTEINS
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Figure 8
Domains II and IV of sEGFR in the unextended, inactive state. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

I and III), which are leucine-rich regions, and CR1 and
CR2 (or II and IV), which are cysteine-rich.23 The
ligand EGF binds to the extracellular domain of the
receptor and leads to receptor dimerization and activation of tyrosine kinase enzyme located in the intracellular
domain of the receptor. Kinase activation leads to transphosphorylation of the receptor intracellular domains
and initiates multiple signal transduction pathways.24
The over expression, mutation or truncation of the EGF
receptor leads to constant activity of the receptor which
results in excess cell growth and, in turn, cancer. EGFR is
implicated in the development of wide range of epithelial
cancers, including those of breast, colon, head and neck,
kidney, lung, pancreas and prostate.25
Unliganded EGF receptors are predominantly in the
unextended form (inactive state) with Domain II buried
by an intramolecular interaction with Domain IV, as
shown in Figure 8.26 Structural studies on EGF-EGFR
complex have shown that the growth factor EGF binds
to the Domains I and III of extracellular-EGFR simultaneously. This binding alters the spatial arrangement of all
extracellular domains (now called the “active, extended
state”) and exposes a critical region, known as the dimerization arm, of Domain II. The unexposed arm intimately assists in the dimerization of the receptor, which
subsequently leads to activation of EGFs intracellular
growth signaling pathway.23,26 We also note that
approximately 10% of unliganded EGFR is in its
extended or “active” state at any given time.23,26
Numerous therapeutic, antagonistic compounds, primarily antibodies, have been developed that bind to
extracellular domains I and III (L1 and L2) of
EGFR.27,28 Herein, however, we looked for a peptide
biomimetic analog of Domain IV, using OpenContact,
that may bind to the exposed arm of Domain II in the
active state of EGFR thereby potentially inhibiting dimerization. Thus, we selected the following input data for
exploration via OpenContact:
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Figure 9
CoarseAB.pdb Output Results from OpenContact for the sEGFR
(Domains II and IV) System. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]

Protein A: 1YY9.pdb Chain A SER501-THR614
(Domain IV residues)
Protein B: 1YY9.pdb Chain A CYS207-CYS309
(Domain II residues)
As shown in Figure 9 from CoarseAB.pdb, one complete (native) loop structure and one linear segment
from Domain IV residues were identified:
First Native Loop: THR570A - LEU595A; (Disulfide
Bridge: CYS571A-CYS593A)
Linear Chain from Part of Second Native Loop:
TYR561A - VAL568A; (Disulfide Bridge: CYS558-CYS567)
The first, 26 residue loop structure is natively stabilized by a disulfide bridge between CYS571-CYS593A.
The second linear peptide overlaps with part of another
disulfide stabilized loop (CYS558-CYS567). Atom–atom
interaction potentials from FineAB.txt show a mixture of
significant van der Waals and partial charge interactions
from both residue sequences (Supporting Information).
The disulfide bond stabilization of these identified
loop structures provided a unique opportunity to investigate the inclusion of secondary structure in peptide
mimetics in addition to the helices studied in previous
cases. Thus, we synthesized a 28 residue segment of the
larger loop (VAL568-LEU595), simply called P28, and
added the disulfide bridge between Cysteine residues.
For kinetic measurements, EGF or P28 at concentrations
ranging from 1 mM to 30 nM and 10 mM to 1 mM, respectively, in running buffer were injected over EGFR at a flow
rate of 30 mL/min for 3 min with dissociation time of 10
min. After each cycle, surfaces were regenerated with 10
mM glycine, pH 1.5. The data was reference subtracted
and fitted to 1:1 Langmuir binding model to obtain the

Contact Mapping for Potential Peptide Mimetics

Figure 10
Response curves from Biacore kinetic binding assays: a: EGF as analyte;
b: P28 as analyte. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]

association rate constant (ka), dissociation rate constant
(kd), and the equilibrium dissociation rate constant (KD).
Figure 10(a,b) shows the initial results of the kinetic
binding assays. For EGF binding [Fig. 10(a)], the calculated equilibrium dissociation constant KD was 92.3 nM
with association rate constant (ka) of 1.75 3 105 M21 s21
and dissociation rate constant (kd) of 0.016 s21. For P28
[Fig. 10(b)], the calculated equilibrium dissociation constant KD was 5 mM with association rate constant (ka) of
67.6 M21 s21 and the dissociation rate constant (kd) of
3.8231024 s21. The equilibrium disassociation constant,
KD, for EGF-EGFR-Fc system shown is consistent with previously published values23 and verifies the activity of the
EGFR-Fc ligand. With only P28 as analyte, as shown in
Figure 10(b), micromolar binding was predicted which is
consistent with only 10% of the ligand in the active state.
Other possibilities of the observed P28 binding include
conformational changes of EGFR-Fc upon surface coupling. More experimental studies are currently underway
in order to pinpoint the binding of P28 with EGFR
domain II. Nonetheless, OpenContact was successful at
identifying a potential peptide mimetic for this system that
included secondary structural components.

DISCUSSION
The simple, static parsing algorithm, OpenContact,
yielded results almost exactly equivalent to proposed

peptide mimetics from four unrelated cases that were
further experimentally studied. The output results
included insights into static force interactions, contact
numbers, secondary structure considerations, recognition
of key residues, and a comprehensive listing of all potential mimetics. The empirical distance and potential cutoffs employed were shown to lead to a manageable, yet
lucrative, numbers of potential peptide mimetics for any
given system. The general format of the output results
allow for more detailed analysis of specific residueresidue and atom–atom interactions by the user for any
given system. All results given here were obtained on an
off-the-shelf, desktop computer with less than a few
minutes of computational time maximum; output files
for each case were less than 1 MB.
We note that potential peptide mimetics identified
through the simple, static contact mapping of protein
interaction partner files can be further screened via more
complex and time-consuming dynamic algorithms, such
as molecular dynamics and docking methods, which are
outside the scope of this work. We also note that the literature experimental case studies on peptidyl biomimetics given here were limited in number and more
experimental studies based on static mapping identification are needed. In addition, future studies are needed to
examine the possibility of strong binding segments of
protein interactions that may only arise through dynamic
studies that are not evident in the static structure analysis given here. Nonetheless, the simple static structure
analysis was shown to quickly and easily uncover potential peptide mimetics that could be “pipe-lined” for further study.
These test cases also nicely demonstrate some of the
challenges associated with the development and application of peptide mimetics. In Case A, the gp41 system,
solubility issues for C34 peptides were encountered
despite their strong binding ability. Cases B, EphB4EphrinB2 and C, Myc-Max, demonstrated that binding
regions associated with particular secondary structural
motifs, such as beta sheets and helices, cannot necessarily
be maintained in isolation. In Case B, only small linear
peptide segments were experimentally possible as mimetics and, in Case C., helical content was improved
through synthetic mutation. Whether or not peptide segments of native protein structure can be maintained in
isolation or to what degree peptide segments can maintain native binding ability will always be an outstanding
issue in the development of peptide mimetics. Case C
also demonstrated the need for complexing peptides for
intracellular drug delivery applications. Case D, our own
experimental peptide development based on static mapping, demonstrates that more sophisticated, native secondary structural maintenance may be possible for some
peptide mimetics. Future improvements to OpenContact,
currently underway, involve the inclusion in the mapping
algorithm of the implicit apolar solvent potentials via the
PROTEINS
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solvent accessible surface area and volume and the addition of conformational flexibility of protein interactions.
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